Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,014 across all filing types
Latest filing 2017-03-30 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
公司章程修正案
Governance Information Classification · 95% confidence The document is titled '章程修正案' which translates to 'Articles of Association Amendment'. It details specific amendments to the company's articles of association, including changes to registered capital, business scope, and share capital structure. It references compliance with Chinese company and securities laws and mentions that the amendments require shareholder approval and regulatory filing. This type of document is related to governance and internal company rules rather than financial performance, audit, or shareholder voting results. Therefore, it fits best under Governance Information (CGR). The document length is short but contains substantive content about governance changes, not just an announcement or notice, so it is not RPA or RNS.
2017-03-30 Chinese
关于子公司收到药品GMP证书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (672 characters) regarding a subsidiary receiving a pharmaceutical GMP certificate from a regulatory authority. It contains no financial data, no report or financial statements, and no mention of voting, management changes, or other report types. It is an official announcement about a regulatory certificate related to product manufacturing compliance. Given the short length and nature of the content, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2017-03-23 Chinese
关于子公司产品抽检不合格情况的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding a quality control issue with certain batches of a pharmaceutical product produced by its subsidiary. It details the product involved, the nature of the non-compliance found in government inspections, the company's response measures including product recall, and the impact on the company's financials and operations. There is no indication that this is a financial report, earnings release, or regulatory filing about financial performance. Instead, it is a regulatory announcement about product quality and compliance with government standards. This fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2017-03-16 Chinese
关于收到药品注册批件的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (773 characters) from a company about receiving a drug registration approval from the National Medical Products Administration (国家食品药品监督管理总局). It contains no financial data, no financial statements, no management discussion, no voting results, no executive changes, no earnings information, and no detailed report content. It is a regulatory announcement about a product approval, which is a regulatory filing type of announcement. It does not fit into categories like Annual Report, Earnings Release, or Capital Update. Given the short length and nature of the content, it is best classified as a Regulatory Filing (RNS).
2017-03-06 Chinese
关于收到药品审批意见通知件的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company regarding receipt of a regulatory notice from the National Medical Products Administration about a drug approval decision. It states the drug registration application was not approved and discusses the impact on the company. The document is short (589 characters) and is an announcement of regulatory feedback rather than a financial report or detailed filing. It does not contain financial statements, management changes, voting results, or other report types. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about compliance and approvals.
2017-03-03 Chinese
2016年度业绩快报
Earnings Release Classification · 95% confidence The document is titled '2016 年度业绩快报' which translates to '2016 Annual Performance Express Report' or '2016 Annual Earnings Quick Report'. It contains preliminary financial data for the year 2016, including revenue, profit, net income, and other financial metrics. The document explicitly states that the data is preliminary, unaudited, and that the final audited data will be disclosed in the annual report. It also mentions that the data is from the company's financial department's initial calculations and has not been audited by an accounting firm. The document is relatively short (2056 characters) and serves as an initial earnings announcement rather than a full annual report. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. It is not a full Annual Report (10-K) or an Audit Report (AR), nor is it a report publication announcement (RPA) because it contains actual preliminary financial data rather than just announcing the release of a report. Therefore, the correct classification is Earnings Release (ER). FY 2016
2017-02-27 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.